BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37]
URL: https://www.wjgnet.com/1948-5182/full/v4/i3/37.htm
Number Citing Articles
1
Alessandra Zannella, Massimo Marignani, Paola Begini. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical ManagementViruses 2019; 11(9): 858 doi: 10.3390/v11090858
2
Michele Barone, Antonella Notarnicola, Giuseppe Lopalco, Maria Teresa Viggiani, Francesco Sebastiani, Michele Covelli, Florenzo Iannone, Alfonso W. Avolio, Alfredo Di Leo, Luca Cantarini, Giovanni Lapadula. Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infectionHepatology 2015; 62(1): 40 doi: 10.1002/hep.27716
3
Melissa Padovan, Matteo Filippini, Angela Tincani, Elisabetta Lanciano, Eleonora Bruschi, Oscar Epis, Pietro Garau, Alessandro Mathieu, Eleonora Celletti, Leopoldo Giani, Paola Tomietto, Fabiola Atzeni, Piercarlo Sarzi Puttini, Francesca Zuliani, Salvatore De Vita, Francesco Trotta, Anastasio Grilli, Massimo Puoti, Marcello Govoni. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus InfectionArthritis Care & Research 2016; 68(6): 738 doi: 10.1002/acr.22786
4
Xiaoming Fei, Fang Lei, Haifeng Zhang, Hua Lu, Yan Zhu, Yu Tang. Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective studySupportive Care in Cancer 2016; 24(6): 2727 doi: 10.1007/s00520-016-3085-6
5
Luca Laurenti, Francesco Autore, Idanna Innocenti, Barbara Vannata, Nicola Piccirillo, Federica Sorà, Domenico Speziale, Maurizio Pompili, Dimitar Efremov, Simona Sica. Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experienceLeukemia & Lymphoma 2015; 56(10): 2841 doi: 10.3109/10428194.2015.1017822
6
Sung-Nan Pei, Chien-Hung Chen. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximabLeukemia & Lymphoma 2015; 56(6): 1611 doi: 10.3109/10428194.2014.964699
7
M.I. Biondo, V. Germano, M. Pietrosanti, M. Canzoni, M. Marignani, T. Stroffolini, S. Salemi, R. D'Amelio. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathiesEuropean Journal of Internal Medicine 2014; 25(5): 482 doi: 10.1016/j.ejim.2013.11.014